ALS

Biogen opts in for Ionis' ALS candidate, plans pivotal trial
Biogen opts in for Ionis' ALS candidate, plans pivotal trial
BioCentury
BIIB067
Biogen
Ionis Pharmaceuticals
ALS
Flag link:
Researchers Cure ALS in Laboratory Animals Using Gene Therapy
Researchers Cure ALS in Laboratory Animals Using Gene Therapy
BioSpace
ALS
Lou Gehrig's disease
gene therapy
University of California
San Diego
Flag link:
PARP inhibitors show promise for treating ALS and other brain disorders
PARP inhibitors show promise for treating ALS and other brain disorders
Fierce Biotech
PARP inhibitors
AstraZeneca
Lynparza
Tesaro
Zejula
ALS
Flag link:
Orion takes repurposed heart failure drug into phase 3 for ALS
Orion takes repurposed heart failure drug into phase 3 for ALS
Fierce Biotech
Orion
ALS
ODM-109
clinical trials
Flag link:
ALS drug maker walks back plan to profit from right-to-try law following heavy criticism
ALS drug maker walks back plan to profit from right-to-try law following heavy criticism
Stat
BrainStorm Cell Therapeutics
right-to-try laws
ALS
clinical trials
NurOwn
Flag link:
Step right up: A biotech may soon sell an experimental med to dying ALS patients under ‘Right to Try’
Step right up: A biotech may soon sell an experimental med to dying ALS patients under ‘Right to Try’
Endpoints
right-to-try laws
ALS
BrainStorm Cell Therapeutics
Flag link:
Flex Pharma dumps midstage trials, cuts workforce, mulls a sale to stay alive
Flex Pharma dumps midstage trials, cuts workforce, mulls a sale to stay alive
Fierce Biotech
Flex Pharma
layoffs
FLX-787
ALS
Flag link:
QurAlis Announces New Investors to Help Fund Drive to Cure ALS
QurAlis Announces New Investors to Help Fund Drive to Cure ALS
CP Wire
QurAlis
ALS
Flag link:
QurAlis Announces New Investors to Help Fund Drive to Cure ALS
QurAlis
ALS
Flag link:
Sangamo shares surge 3.4% on $12 mln ALS gene therapy collaboration with Pfizer
Sangamo shares surge 3.4% on $12 mln ALS gene therapy collaboration with Pfizer
Marketwatch
Sangamo
Pfizer
ALS
gene therapy
drug development
Flag link:
New target could yield treatment for Alzheimer's, ALS and more
New target could yield treatment for Alzheimer's, ALS and more
Fierce Biotech
Genentech
Roche
drug development
R&D
Alzheimer's disease
ALS
Flag link:
The First ALS Drug In 22 Years Is Approved -- And It Costs 4 Times What It Does In Japan
The First ALS Drug In 22 Years Is Approved -- And It Costs 4 Times What It Does In Japan
Forbes
ALS
drug pricing
MT Pharma
Radicava
Flag link:
FDA OKs stem cell-gene therapy trial for ALS
FDA OKs stem cell-gene therapy trial for ALS
Drug Delivery Business
FDA
stem cells
gene therapy
ALS
Flag link:
Backed by a biotech legend, two young entrepreneurs tackle one of the Holy Grails of R&D
Backed by a biotech legend, two young entrepreneurs tackle one of the Holy Grails of R&D
Endpoints
R&D
startups
ALS
Lou Gehrig's disease
Amylyx
Henri Termeer
Flag link:
Brainstorm: New ALS Stem Cell Results Support Start of Pivotal Clinical Trial
Brainstorm: New ALS Stem Cell Results Support Start of Pivotal Clinical Trial
TheStreet.com
BrainStorm Cell Therapeutics
stem cells
clinical trials
ALS
NurOwn
Flag link:
Biogen, Columbia to Map ALS Disease Genes With Ice Bucket Money
Biogen, Columbia to Map ALS Disease Genes With Ice Bucket Money
Bloomberg
Biogen
Columbia University
ALS
social media
Flag link:
How a drug shift set the stage for a potential winner for ALS patients
How a drug shift set the stage for a potential winner for ALS patients
Bizjournals.com
ALS
Lou Gehrig's disease
Tirasemtiv
Cytokinetics
Flag link:
Teva Pharm told to return intellectual property to Proneuron Biotechnologies
Teva Pharm told to return intellectual property to Proneuron Biotechnologies
Yahoo/Reuters
Teva Pharmaceutical
Proneuron Biotechnologies
ALS
Flag link:
What's driving the massive social media campaign for Genervon's ALS drug?
What's driving the massive social media campaign for Genervon's ALS drug?
Fierce Biotech
social media
Genervon
ALS
Lou Gehrig's disease
compassionate use guidelines
Flag link:
The FDA calls on Genervon to release data from controversial ALS study
The FDA calls on Genervon to release data from controversial ALS study
Fierce Biotech
FDA
Genervon
ALS
GM604
Flag link:

Pages